Evaluating Safety and Survival of Neoadjuvant Immunotherapy in Surgery and Radiotherapy for Non-Small Cell Lung Cancer in a Real-World Study

What this Trial Is About

Researchers are evaluating the safety, effectiveness, and survival results of neoadjuvant or induction immunotherapy in patients with non-small cell lung cancer NSCLC. This study focuses on real-world outcomes across multiple centers, including patients undergoing surgery, definitive radiotherapy, or non-surgical treatments. It aims to fill gaps left by previous trials by including a diverse patient group, covering treatment from the initial immunotherapy phase through surgery and follow-up, to better support clinical decisions for both operable and inoperable cases. The study observes patients who have received neoadjuvant immune checkpoint inhibitors, such as PD-1PD-L1 blockers, either alone or combined with chemotherapy. All treatments, including surgery and radiotherapy, follow routine care as determined by the patients doctors. This retrospective observational design collects data on various treatment paths to assess outcomes in normal clinical practice. Participants medical records are reviewed to analyze technical surgical difficulty, disease-free survival, postoperative complications, treatment-related adverse events, and other key clinical outcomes. The study includes follow-up periods of up to five years to monitor progression-free and overall survival. This comprehensive data collection helps provide real-world evidence on the benefits and risks of neoadjuvant immunotherapy in NSCLC management.

Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer